Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

40.40 -0.38 (-0.94%)
Streaming Delayed Price Updated: 9:38 AM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
News headline image
Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year ↗
In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity. 
Via Stocktwits
News headline image
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars ↗
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
News headline image
Market Movers: $ASTS Surges Again, $PBI Gears Up For Earnings! ↗
Pre-Market Briefing: Feb 6 – Top trade setups using our 4-pillar strategy! $ASTS leads the way, $PBI gears up for earnings, and $PTON & $APPS ride post-earnings momentum. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Has the Bubble Burst for Viking Therapeutics Stock? ↗
Via The Motley Fool
News headline image
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why. ↗
Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For February 5, 2025 ↗
 
Via Benzinga
News headline image
(VKTX) - Analyzing Viking Therapeutics's Short Interest ↗
 
Via Benzinga
News headline image
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025? ↗
Via The Motley Fool
News headline image
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates ↗
Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the details from the report. 
Via Benzinga
News headline image
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy? ↗
Wall Street has high hopes for development-stage pharmaceutical company Viking Therapeutics. 
Via The Motley Fool
News headline image
Jim Cramer: This Industrial Stock Is 'Absolutely Terrific', First Solar Is 'Very Inexpensive' ↗
First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on Tuesday, Feb. 25, 2025. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results ↗
The Danish drug giant reported a 22% weight loss over 36 weeks. 
Via Investor's Business Daily
News headline image
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks That Could Blast Off This Quarter ↗
 
Via Benzinga
News headline image
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today ↗
Via The Motley Fool
News headline image
We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks ↗
Oppenheimer earlier this month listed Viking as one of five biotech companies that could be prime candidates for an "aspirational" takeover. 
Via Stocktwits
News headline image
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday ↗
Via The Motley Fool
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
3 Mid-Cap Stocks That Could Take Off in 2025 ↗
Via The Motley Fool
News headline image
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst ↗
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
News headline image
1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street Analysts ↗
This is a high-risk, high-reward stock. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Plummeted by 24% in December ↗
Via The Motley Fool
News headline image
Should You Buy the Dip on This High-Flying Stock? ↗
Via The Motley Fool
News headline image
StoryTrading's Secrets To January Gains - Don’t Miss These Picks ↗
As we usher in the new year, market dynamics continue to be shaped by a blend of tax-deferral selling, the January effect, and macro uncertainties. 
Via Talk Markets
Topics Stocks / Equities
News headline image
3 Stocks That Could Be Monster Winners in 2025 ↗
Via The Motley Fool
News headline image
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck? ↗
Via The Motley Fool
News headline image
My Top 10 Stocks to Buy for 2025 ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Tumbled by More Than 10% This Week ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.